UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/522,153	10/31/2005	Teruo Kirikae	Q85911	9240
65565 SUGHRUE-26	7590 12/10/2007		EXAMINER	
2100 PENNSY	LVANIA AVE. NW		KIM, YUNSOO	
WASHINGTO	N, DC 20037-3213		ART UNIT	PAPER NUMBER
			1644	
			MAIL DATE	DELIVERY MODE
			12/10/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<u> </u>		
	Application No.	Applicant(s)
	10/522,153	KIRIKAE ET AL.
Office Action Summary	Examiner	Art Unit
	Yunsoo Kim	1644
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet v	vith the correspondence address
A SHORTENED STATUTORY PERIOD FOR REF WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by sta Any reply received by the Office later than three months after the may earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUN 1.136(a). In no event, however, may a od will apply and will expire SIX (6) MO tute, cause the application to become A	ICATION. reply be timely filed NTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on This action is FINAL . 2b) ☑ To a since this application is in condition for allow closed in accordance with the practice under the practice.	his action is non-final. vance except for formal ma	•
Disposition of Claims		
4) ☐ Claim(s) <u>1-32</u> is/are pending in the application 4a) Of the above claim(s) is/are withd 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) <u>1-32</u> are subject to restriction and/or	rawn from consideration.	
Application Papers		
9) The specification is objected to by the Exami	iner.	
10) The drawing(s) filed on is/are: a) a	ccepted or b) objected to	by the Examiner.
Applicant may not request that any objection to the	he drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the corr		
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for forei a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a least open content.	ents have been received. ents have been received in a riority documents have been eau (PCT Rule 17.2(a)).	Application No n received in this National Stage
Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)		Summary (PTO-413) (s)/Mail Date
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 		Informal Patent Application

10/522,153 Art Unit: 1644

DETAILED ACTION

- 1. Claims 1-32 are pending.
- 2. Restriction is required under 35 U.S.C. 121 and 372. This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-6, 30 and 32, drawn to an antibody binds to a peptide consisting of the amino acid represented by SEQ ID NO:1.

Group II, claim(s) 7-19 and 25-29, drawn to a method for assaying or detecting a peptide comprising SEQ ID NO:1.

Group III, claim(s) 20-24 and 30-31 drawn to a kit for assaying or diagnosing a peptide comprising SEQ ID NO:1.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions of Groups I-III were found to have no special technical features that defined the contribution over the prior art of Hitara (EP 0 955 312 A2, IDS reference) and Campbell (Monoclonal Antibody Technology, 1984, p. 1-30).

The '312 publication teaches the antimicrobial peptides as in SEQ ID NOs: 1-3.

Campbell teaches that it is customary for any group working on a protein to make monoclonal antibody to it (p. 29) and that monoclonal antibodies are useful for therapeutic, diagnostic, preparative and basic research purposes.

Application/Control Number:

10/522,153

Art Unit: 1644

Since Applicants' inventions do not contribute a special technical feature when viewed over the prior art, or meet key critical elements, they do not have a single general inventive concept and so lack unity of invention.

3. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yunsoo Kim whose telephone number is 571-272-3176. The examiner can normally be reached on M-F,9-5. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number:

10/522,153 Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Yunsoo Kim
Patent Examiner
Technology Center 1600
December 6, 2007

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600